GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Shiller PE Ratio

Agenus (FRA:AJ8) Shiller PE Ratio : (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Agenus Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agenus Shiller PE Ratio Historical Data

The historical data trend for Agenus's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Shiller PE Ratio Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agenus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agenus's Shiller PE Ratio

For the Biotechnology subindustry, Agenus's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Agenus's Shiller PE Ratio falls into.



Agenus Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Agenus's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Agenus's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-55.936/131.7762*131.7762
=-55.936

Current CPI (Mar. 2024) = 131.7762.

Agenus Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1.914 100.560 -2.508
201409 -2.018 100.428 -2.648
201412 -6.650 99.070 -8.845
201503 -5.174 99.621 -6.844
201506 -9.445 100.684 -12.362
201509 -2.851 100.392 -3.742
201512 -3.305 99.792 -4.364
201603 -6.645 100.470 -8.716
201606 -5.874 101.688 -7.612
201609 -8.375 101.861 -10.835
201612 -5.688 101.863 -7.358
201703 -3.366 102.862 -4.312
201706 -5.696 103.349 -7.263
201709 -6.209 104.136 -7.857
201712 -5.915 104.011 -7.494
201803 -8.597 105.290 -10.760
201806 -4.109 106.317 -5.093
201809 -4.971 106.507 -6.150
201812 -7.032 105.998 -8.742
201903 2.124 107.251 2.610
201906 -6.726 108.070 -8.201
201909 -5.993 108.329 -7.290
201912 -3.960 108.420 -4.813
202003 -5.611 108.902 -6.790
202006 -4.973 108.767 -6.025
202009 -4.754 109.815 -5.705
202012 -2.959 109.897 -3.548
202103 -4.536 111.754 -5.349
202106 -6.142 114.631 -7.061
202109 12.240 115.734 13.937
202112 -5.310 117.630 -5.949
202203 -3.450 121.301 -3.748
202206 -3.216 125.017 -3.390
202209 -3.838 125.227 -4.039
202212 -4.531 125.222 -4.768
202303 -80.511 127.348 -83.311
202306 -3.692 128.729 -3.779
202309 -2.998 129.860 -3.042
202312 -2.201 129.419 -2.241
202403 -55.936 131.776 -55.936

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agenus  (FRA:AJ8) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Agenus Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Agenus's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (FRA:AJ8) Business Description

Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines